Cartalax is a short bioregulatory peptide with widespread systemic impact due to its effects on fibroblasts. It has been shown to benefit skin and other connective tissues as well as the kidneys. Research shows that Cartalax increases cell proliferation rates and beneficially alters the levels of various cytokines and signaling molecules associated with senescence. Overall, it increases cell health and proliferation while decreasing cell death. Cartalax is thought of as an anti-aging peptide, returning older cells to a more youthful state and prolonging overall tissue health.
Reducing apoptosis while increasing proliferation sounds REALLY sketchy to me unless we are 100% certain where, how, and for how long this effect lasts.